JNJ
JOHNSON & JOHNSON
NYSE: JNJ · New Brunswick, NJ · Healthcare
$263.40+4.13 (+1.59%)Closed
Market Cap$634.77B
Cash$20.76Bmost recent
Runwayprofitable
P/E (TTM)23.9EPS $11.03
52-Wk Range$160.72 – $267.24
Avg Volume8.5M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$263.40+74.6%
Pipeline

Drug candidates sponsored by JOHNSON & JOHNSON · ClinicalTrials.gov

83 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Cetirizine
Allergic Rhinitis+3 more
Completed
2001-07past
1
Phase 4OROS-methylphenidate
Attention Deficit Hyperactivity Disorder
Completed
2007-06past
1
Phase 4Placebo
Infant, Premature+2 more
Terminated
2009-03past
2
Phase 4Paliperidone extended-release
Schizophrenia
Terminated
2015-06past
1
Phase 4Bortezomib
Multiple Myeloma
Completed
2015-07past
2
Phase 4Listerine Experimental Mouthwash
Healthy
Completed
2023-08-03past
1
Phase 4tramadol hydrochloride; acetaminophen
Pain
Completed—1
Phase 4risperidone, quetiapine
Schizophrenia+1 more
Completed—1
Phase 4Ibuprofen
Pain
Completed—1
Phase 3Tapentadol extended release (ER)
Diabetic Neuropathy, Painful+1 more
Terminated
2010-04past
1
Phase 3Rivaroxaban
Atrial Fibrillation+2 more
Completed
2010-09past
1
Phase 3Bumetanide
Cirrhosis
Recruiting
2029-03-01
1
Phase 3topiramate
Bipolar Disorders+10 more
Completed—6
Phase 3levofloxacin
Prostatitis+1 more
Completed—2
Phase 3epoetin alfa
Stomach Neoplasms+9 more
Completed—8
Phase 3CAELYX
Ovarian Neoplasms
Terminated—1
Phase 3Paliperidone palmitate
Schizophrenia
Completed—1
Phase 3galantamine hydrobromide
Alzheimer Disease+1 more
Completed—1
Phase 3risperidone
Dementia+4 more
Completed—2
Phase 3Risperidone long-acting injectable
Schizophrenia
Completed—1
Phase 3Topiramate; Carbamazepine; Valproate
Epilepsy+1 more
Completed—1
Phase 2ZARNESTRA, tipifarnib, R115777
Breast Cancer+1 more
Completed
2005-10past
2
Phase 2Blink® Tears eye drops in a multidose bottle
Visual Acuity
Completed
2023-05-06past
1
Phase 2JNJ-90301900
Carcinoma, Non-Small-Cell Lung
Recruiting
2028-12-31
1
Phase 2tipifarnib (R115777)
Leukemia, Nonlymphocytic, Acute
Completed—1
Phase 1Diphenhydramine hydrochloride
Nasal Congestion
Completed
2006-11past
1
Phase 1famotidine (+) calcium carbonate (+) magnesium hydroxide tablet
Heartburn
Completed
2008-03past
1
Phase 1Glyburide
Healthy
Completed
2008-09past
1
Phase 1divalproex sodium ER/paliperidone ER
Schizophrenia+2 more
Completed
2009-04past
1
Phase 1JNJ-39393406
Healthy
Completed
2009-06past
1
Phase 1JNJ-40411813
Healthy
Completed
2010-05past
1
Phase 1tapentadol (CG5503) ER two 100-mg TRF
Healthy Volunteer
Completed—1
Phase 1Topiramate oral liquid formulation;Topiramate Sprinkle formulation
Epilepsy
Completed—1
Phase 1JNJ-39439335, Placebo
Pain
Completed—1
Phase 114C-paliperidone
Schizophrenia
Completed—1
Phase 1R306465
Neoplasms
Completed—1
Phase 1paliperidone palmitate 100 mg
Schizophrenia
Completed—1
N/AUnnamed
Allergy
Completed
2004-11past
1
N/AUnnamed
Healthy Term Infants
Completed
2009-10past
1
N/AUnnamed
Myopia
Completed
2010-05-01past
1
N/AUnnamed
Dentin Sensitivity
Completed
2010-07past
1
N/AUnnamed
Blister
Completed
2010-11past
1
N/AUnnamed
Metastatic Breast Cancer+1 more
Completed
2011-06-22past
1
N/AUnnamed
Cardiovascular Disease+1 more
Terminated
2011-11past
1
N/ATapentadol IR
Substance Abuse Detection
Completed
2012-02past
1
N/AUnnamed
Growth of Term Infants
Completed
2012-12past
1
N/AUnnamed
Refractive Error
Completed
2013-08past
1
N/AUnnamed
Myopia
Completed
2014-03past
1
N/AUnnamed
Lapsed Contact Lens Wear
Completed
2014-04past
1
N/AUnnamed
Dentin Sensitivity
Completed
2014-05past
1
N/AUnnamed
Shoulder Dislocation
Completed
2014-10past
1
N/AUnnamed
Acute Ischemic Stroke
Completed
2014-11past
1
N/AUnnamed
Corneal Swelling
Completed
2015-04past
1
N/AUnnamed
Visual Acuity
Completed
2015-06-01past
1
N/AUnnamed
Visual Acuity
Completed
2015-08past
1
N/AUnnamed
Vision Correction
Completed
2015-09-01past
1
N/AUnnamed
Myopia; Astigmatism
Completed
2015-11past
1
N/AUnnamed
Visual Disorder
Completed
2016-03past
1
N/AUnnamed
Cognitive Ability, General
Completed
2016-10past
1
N/AUnnamed
Blood Glucose Measurement
Withdrawn
2016-11-30past
1
N/AUnnamed
Visual Acuity
Completed
2017-07-21past
1
N/AUnnamed
Rheumatoid Arthritis+2 more
Completed
2017-12-04past
1
N/AUnnamed
Rheumatoid Arthritis
Completed
2018-03past
1
N/AUnnamed
Healthy Volunteers
Completed
2018-03-23past
1
N/AUnnamed
Visual Acuity
Completed
2019-03-25past
1
N/AUnnamed
Ichthyosis+1 more
Completed
2019-12-18past
1
N/AUnnamed
Visual Acuity
Completed
2020-03-28past
1
N/AUnnamed
Visual Acuity
Completed
2020-12-09past
1
N/AUnnamed
Visual Acuity
Withdrawn
2021-01-06past
1
N/AUnnamed
Visual Acuity
Completed
2021-08-12past
1
N/AUnnamed
Visual Acuity
Completed
2021-11-29past
1
N/AUnnamed
Healthy
Completed
2022-01-20past
1
N/AUnnamed
Cataract
Completed
2022-06-17past
1
N/AUnnamed
Visual Acuity
Completed
2022-07-22past
1
N/AUnnamed
Visual Acuity
Completed
2022-08-09past
1
N/AUnnamed
High Risk Localized Prostate Cancer
Completed
2023-06-07past
1
N/AUnnamed
Visual Acuity
Completed
2024-06-24past
1
N/AUnnamed
Healthy
Completed
2025-02-20past
1
N/AUnnamed
Visual Acuity
Completed
2025-10-16past
1
N/AUnnamed
Tilt and Decentration
Completed
2026-01-16past
1
N/AUnnamed
Growth
Not yet recruiting
2026-12-01
1
N/AUnnamed
Intracranial Aneurysm
Recruiting
2028-02-10
1
N/AUnnamed
Cognitive Development+1 more
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for JNJ. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.